Latest Compliance News

Block, Inc. reported a modest 2% revenue increase in Q3 2025 driven by growth in its Cash App and Square segments, alongside a $461.5 million net income. The company issued $2.2 billion in senior notes and repurchased $1.5 billion in stock, while navigating ongoing regulatory scrutiny and legal challenges.

Trading in Alliance Aviation Services Limited (AQZ) shares has resumed following the lifting of a suspension tied to a recent trading update announcement.

Alliance Aviation Services has lowered its FY26 earnings guidance significantly below analyst expectations, citing increased depreciation, higher maintenance costs, and a contract dispute. Despite these challenges, the company maintains profitability and a strong balance sheet.

Tivan Limited has initiated a comprehensive program of works at its recently acquired Molyhil Tungsten-Molybdenum Project, setting the stage for drilling and resource expansion in early 2026.

AVITA Medical reported an 18% revenue increase in Q3 2025 driven by new product launches and deeper market penetration, while continuing to face net losses and credit covenant challenges. The company also announced a CEO departure and interim leadership appointment.

Macquarie Group Limited reported a 3% increase in half-year profit to $1.655 billion, driven by growth across its asset management, banking, commodities, and capital markets divisions. The group maintains robust capital and liquidity positions despite margin pressures and regulatory challenges.

Aeris Resources has completed an $80 million equity placement and launched a share purchase plan, strengthening its balance sheet and setting ambitious production targets for FY26. The company is also divesting non-core assets to focus on growth and exploration.

Finexia Financial Group Limited (ASX – FNX) has had its trading suspension lifted immediately following its public response to recent media speculation. The reinstatement marks a pivotal moment for the financial group’s market activity.

Finexia Financial Group has formally ended preliminary discussions with Salter Brothers regarding a potential reverse listing and is seeking immediate reinstatement of its ASX securities.

ALS Limited has responded to an ASX inquiry regarding the delayed lodgement of key disclosure documents related to performance rights granted to director Malcolm Deane, attributing the delay to human error and outlining steps to reinforce compliance.

James Hardie Industries faces intense scrutiny from the ASX after its share price dropped sharply and trading volumes spiked, prompting urgent questions about undisclosed information.

Chimeric Therapeutics has responded to ASX inquiries regarding the disclosure timing and materiality of new clinical data from its ADVENT-AML trial, emphasizing compliance with continuous disclosure rules and the careful verification of promising patient responses.